Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: Pharmacology and clinical outcomes

Expert Review of Clinical Pharmacology

Volumn 9, Issue 1, 2016, Pages 35-48

  Richardson, Paul G ^a   Harvey, R Donald ^b   Laubach, Jacob P ^a   Moreau, Philippe ^c   Lonial, Sagar ^b   San Miguel, Jesús F ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b EMORY UNIVERSITY   (United States)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

bortezomib; deacetylase inhibitors; multiple myeloma; panobinostat; relapsed and refractory multiple myeloma

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CELLULAR RETINOL BINDING PROTEIN 1; DEXAMETHASONE; GLUTATHIONE PEROXIDASE 3; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 6; LENALIDOMIDE; NONHISTONE PROTEIN; OSTEONECTIN; PANOBINOSTAT; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER FATIGUE; CANCER RECURRENCE; CONTROLLED CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG ABSORPTION; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HYDROLYSIS; DRUG INTERACTION; DRUG OXIDATION; EPIGENETICS; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; HUMAN; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA CELL; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; QT PROLONGATION; QTC INTERVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; RENAL CLEARANCE; REVIEW; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT DURATION; DISEASE FREE SURVIVAL; GENETIC EPIGENESIS; PATHOLOGY; RECURRENT DISEASE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; MULTIPLE MYELOMA; RECURRENCE;

EID: 84949090584     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2016.1096773     Document Type: Review

References (49)

1. Katzel JA, Hari P, Vesole DH. Multiple myeloma: charging toward a bright future. CA Cancer J Clin. 2007; 57: 301-318
2. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011; 364: 1046-1060
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65: 5-29
4. Kumar SK, Rajkumar SV, Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111: 2516-2520
5. Kumar SK, Lee JH, Lahuerta JJ., et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia. 2012; 26: 149-157
6. Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. 2011; 10: 2034-2042
7. Choudhary C, Kumar C, Gnad F., et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009; 325: 834-840
8. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009; 280: 233-241
9. Kaiser MF, Johnson DC, Wu P., et al. Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood. 2013; 122: 219-226
10. Kalushkova A, Fryknas M, Lemaire M., et al. Polycomb target genes are silenced in multiple myeloma. PLoS One. 2010; 5: e11483
11. Moreaux J, Reme T, Leonard W., et al. Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. Br J Cancer. 2013; 109: 676-685
12. Mithraprabhu S, Kalff A, Chow A., et al. Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics. 2014; 9: 1511-1520
13. Kawaguchi Y, Kovacs JJ, McLaurin A., et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell. 2003; 115: 727-738
14. Hideshima T, Bradner JE, Wong J., et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA. 2005; 102: 8567-8572
15. Catley L, Weisberg E, Kiziltepe T., et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006; 108: 3441-3449
16. Kikuchi J, Wada T, Shimizu R., et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood. 2010; 116: 406-417
17. Clive S, Woo MM, Nydam T., et al. Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients. Cancer Chemother Pharmacol. 2012; 70: 513-522
18. Wolf JL, Siegel D, Goldschmidt H., et al. A phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012; 53: 1820-1823
19. Garnock-Jones KP. Panobinostat: first global approval. Drugs. 2015; 75: 695-704
20. Shapiro GI, Frank R, Dandamudi UB., et al. The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer. Cancer Chemother Pharmacol. 2012; 69: 555-562
21. Hamberg P, Woo MM, Chen LC., et al. Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemother Pharmacol. 2011; 68: 805-813
22. Feld R, Woo MM, Leighl N., et al. A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer. Cancer Chemother Pharmacol. 2013; 72: 747-755
23. DeAngelo DJ, Spencer A, Bhalla KN., et al. Phase Ia/II, two-Arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia. 2013; 27: 1628-1636
24. Giles F, Fischer T, Cortes J., et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006; 12: 4628-4635
25. Sharma S, Beck J, Mita M., et al. A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors. Invest New Drugs. 2013; 31: 974-985
26. Grzasko N, Morawska M, Hus M. Optimizing the treatment of patients with multiple myeloma and renal impairment. Clin Lymphoma Myeloma Leuk. 2015; 15: 187-198
27. Sharma S, Witteveen PO, Lolkema MP., et al. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. Cancer Chemother Pharmacol. 2015; 75: 87-95
28. Slingerland M, Hess D, Clive S., et al. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function. Cancer Chemother Pharmacol. 2014; 74: 1089-1098
29. San-Miguel JF, Richardson PG, Gunther A., et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013; 31: 3696-3703
30. Richardson P, Mitsiades C, Colson K., et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008; 49: 502-507
31. Niesvizky R, Ely S, Mark T., et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2011; 117: 336-342
32. Richardson PG, Schlossman RL, Alsina M., et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013; 122: 2331-2337
33. San-Miguel JF, Hungria VT, Yoon SS., et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014; 15: 1195-1206
34. Campos MP, Hassan BJ, Riechelmann R., et al. Cancer-related fatigue: a practical review. Ann Oncol. 2011; 22: 1273-1279
35. Moreau P, Pylypenko H, Grosicki S., et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011; 12: 431-440
36. Giver CR, Jaye DL, Waller EK., et al. Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes. Leukemia. 2011; 25: 362-365
37. Bishton MJ, Harrison SJ, Martin BP., et al. Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood. 2011; 117: 3658-3668
38. Lonial S, Waller EK, Richardson PG., et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005; 106: 3777-3784
39. Zhang L, Lebwohl D, Masson E., et al. Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat). J Clin Oncol. 2008; 26: 332-333
40. Dimopoulos MA, Moreau P, Palumbo A., et al. Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): results from the phase III study ENDEAVOR. J Clin Oncol. 2015; 33 (suppl) [. abstract 8509 ]. [cited 2015 Oct 14]. Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/15-suppl/8509
41. Laubach JP, Voorhees PM, Hassoun H., et al. Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Rev Hematol. 2014; 7: 97-111
42. Weber DM, Chen C, Niesvizky R., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007; 357: 2133-2142
43. Dimopoulos M, Spencer A, Attal M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007; 357: 2123-2132
44. Dimopoulos MA, Stewart AK, Rajkumar SV., et al. Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391). J Clin Oncol. 2015; 33 (suppl) [. abstract 8525 ]. [cited 2015 Oct 14]. Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/15-suppl/8525
45. Richardson PG, Siegel DS, Vij R., et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014; 123: 1826-1832
46. Lonial S, Dimopoulos M, Palumbo A., et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015 [. Epub ahead of print ].
47. Lonial S, Weiss BM, Usmani SZ., et al. Phase II study of daratumumab (DARA) monotherapy in patients with ≥3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius). J Clin Oncol. 2015; 33 (suppl) [. abstract LBA8512 ]. [cited 2015 Oct 14]. Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/15-suppl/LBA8512
48. Romano A, Conticello C, Cavalli M., et al. Salvage therapy of multiple myeloma: the new generation drugs. Biomed Res Int. 2014; 2014: 456037
49. Ocio EM, Vilanova D, Atadja P., et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica. 2010; 95: 794-803